Woodmont Investment Counsel LLC Increases Position in Moderna, Inc. (NASDAQ:MRNA)

Woodmont Investment Counsel LLC grew its holdings in Moderna, Inc. (NASDAQ:MRNA) by 63.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,188 shares of the company’s stock after purchasing an additional 8,218 shares during the quarter. Woodmont Investment Counsel LLC’s holdings in Moderna were worth $1,416,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in MRNA. Ashton Thomas Private Wealth LLC purchased a new stake in Moderna in the 2nd quarter valued at $26,000. Family Firm Inc. acquired a new stake in Moderna during the second quarter worth about $33,000. Cedar Wealth Management LLC raised its stake in Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after purchasing an additional 90 shares during the period. Bank & Trust Co acquired a new position in Moderna in the 2nd quarter valued at about $36,000. Finally, Hanseatic Management Services Inc. acquired a new stake in shares of Moderna during the 2nd quarter worth approximately $48,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Price Performance

Shares of MRNA opened at $51.81 on Thursday. The firm has a market capitalization of $19.92 billion, a PE ratio of -3.37 and a beta of 1.69. The stock’s 50 day moving average is $63.00 and its two-hundred day moving average is $99.97. Moderna, Inc. has a twelve month low of $49.60 and a twelve month high of $170.47. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. The Goldman Sachs Group cut their target price on Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a research note on Monday, September 16th. Leerink Partners decreased their price target on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research note on Tuesday, September 17th. Oppenheimer cut Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. Bank of America lowered their target price on Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a report on Friday, September 13th. Finally, HSBC upgraded shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price target on the stock in a research note on Wednesday, August 28th. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Moderna presently has an average rating of “Hold” and a consensus price target of $94.00.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,184 shares of company stock valued at $238,531 over the last quarter. Company insiders own 15.20% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.